Amin covers the Healthcare sector, focusing on stocks such as Ocular Therapeutix, Apellis Pharmaceuticals, and BridgeBio Pharma. The word on The Street in general, suggests a Strong Buy analyst ...

The company’s shares closed yesterday at $14.92. Samimy covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Viking Therapeutics, and Apellis Pharmaceuticals. According to ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Peer Ratings Comparison In this comparison, we explore the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three ...

In this comparison, we explore the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three prominent industry players ...

The below comparison of the analyst ratings and average 1-year price targets of Iovance Biotherapeutics, Apellis Pharmaceuticals and Amicus Therapeutics, three prominent players in the industry ...

Kymera Therapeutics (NASDAQ:KYMR) is preparing to release its quarterly earnings on Thursday, 2024-10-31. Here's a brief overview of what investors should keep in mind before the announcement.

AUPH), Apellis Pharmaceuticals (NASDAQ: APLS), Checkmate Pharmaceuticals (NASDAQ: CMPI, acquired by Regeneron), Turning Point Therapeutics (NASDAQ: TPTX, acquired by BMS), Akero Therapeutics ...

On Monday, Citi reaffirmed its Buy rating on Apellis Pharmaceuticals (NASDAQ:APLS) stock with a steady price target of $63.00. The endorsement follows the company's presentation at the American ...